{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine+injection&page=5",
    "query": {
      "intervention": "Insulin glargine injection",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 119,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine+injection&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine+injection&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T18:19:19.011Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00309244",
      "title": "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Type 2"
      ],
      "interventions": [
        {
          "name": "Technosphere® Insulin Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 677,
      "start_date": "2006-02",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-10-16",
      "last_synced_at": "2026-10-14T18:19:19.011Z",
      "location_count": 80,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00309244"
    },
    {
      "nct_id": "NCT00838916",
      "title": "A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "albiglutide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 779,
      "start_date": "2009-02",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-10-14T18:19:19.011Z",
      "location_count": 314,
      "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 252 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Hueytown",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00838916"
    },
    {
      "nct_id": "NCT00437112",
      "title": "Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Human Insulin Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2007-02",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2018-03-09",
      "last_synced_at": "2026-10-14T18:19:19.011Z",
      "location_count": 6,
      "location_summary": "Greenbrae, California • Topeka, Kansas • Toms River, New Jersey + 3 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        },
        {
          "city": "Toms River",
          "state": "New Jersey"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "New Braunfels",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00437112"
    },
    {
      "nct_id": "NCT04974528",
      "title": "Afrezza® INHALE-1 Study in Pediatrics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Afrezza",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rapid-acting Insulin Analog",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Basal Insulin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Years to 17 Years"
      },
      "enrollment_count": 319,
      "start_date": "2021-09-29",
      "completion_date": "2025-04-29",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-10-14T18:19:19.011Z",
      "location_count": 39,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 35 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04974528"
    },
    {
      "nct_id": "NCT02846233",
      "title": "Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "GLP1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "basal insulin",
          "type": "DRUG"
        },
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2016-08",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2020-11-10",
      "last_synced_at": "2026-10-14T18:19:19.011Z",
      "location_count": 1,
      "location_summary": "Fresno, California",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846233"
    },
    {
      "nct_id": "NCT02843399",
      "title": "Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 15498,
      "start_date": "2016-08-15",
      "completion_date": "2016-12-15",
      "has_results": false,
      "last_update_posted_date": "2017-12-15",
      "last_synced_at": "2026-10-14T18:19:19.011Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02843399"
    },
    {
      "nct_id": "NCT05114590",
      "title": "Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine/Lixisenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2022-01-27",
      "completion_date": "2023-04-14",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-10-14T18:19:19.011Z",
      "location_count": 18,
      "location_summary": "Canyon Country, California • Huntington Park, California • Lomita, California + 13 more",
      "locations": [
        {
          "city": "Canyon Country",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05114590"
    },
    {
      "nct_id": "NCT03260868",
      "title": "Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine, 300 units per milliliter (U/mL)",
          "type": "DRUG"
        },
        {
          "name": "Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-09-19",
      "completion_date": "2018-11-22",
      "has_results": true,
      "last_update_posted_date": "2022-04-07",
      "last_synced_at": "2026-10-14T18:19:19.011Z",
      "location_count": 3,
      "location_summary": "West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia",
      "locations": [
        {
          "city": "West Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Bridgeport",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03260868"
    },
    {
      "nct_id": "NCT00360698",
      "title": "Insulin Glulisine in Type 2 Diabetic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        },
        {
          "name": "Glimepiride",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glulisine",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 106,
      "start_date": "2006-07",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2011-08-08",
      "last_synced_at": "2026-10-14T18:19:19.011Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00360698"
    },
    {
      "nct_id": "NCT00551538",
      "title": "24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Lispro mix 75/25",
          "type": "DRUG"
        },
        {
          "name": "Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2003-05",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2010-10-13",
      "last_synced_at": "2026-10-14T18:19:19.011Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00551538"
    }
  ]
}